ReviewEndocrinology2026
The expanding landscape of the glucagon signaling network: mechanisms and outcomes.
Review in Endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Glucagon is a peptide hormone mainly secreted by the alpha cells of the pancreatic islets in response to nutritional stimuli. Traditionally recognized for its hyperglycemic function counteracting insulin action, it mainly acts on the liver to affect glycogen, amino acid, lipid, and energy metabolism. Beyond its metabolic effects, glucagon also increases hepatocyte cell survival and reduces viral replication. Peptides with glucagon activity have recently emerged as a promising therapeutic candidate for obesity, type 2 diabetes, and associated liver disease, with several glucagon-based agents currently in phase 2/3 clinical trials. Despite this progression, and although discovered roughly the same time as insulin, how glucagon exerts its pleiotropic effects on metabolism and beyond remains relatively poorly understood. Knowledge of these signaling pathways could pave the way for further refinement of glucagon-based pharmacotherapy with more pronounced effects or reduced side effects. This review aims to address established literature and its limitations on glucagon signaling mechanisms and provides an update on the state of the art on glucagon signaling pathways to help in understanding the mechanisms behind glucagon action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.